Zobrazeno 1 - 10
of 118
pro vyhledávání: '"Yvona Brychtová"'
Autor:
Martin Šimkovič, Peter Turcsányi, Martin Špaček, Jana Mihályová, Pavlína Ryznerová, Mária Maco, Pavel Vodárek, Dominika Écsiová, Hynek Poul, Heidi Móciková, Jana Zuchnická, Anna Panovská, Mohammad Lekaa, Martina Oršulová, Adéla Prchlíková, Lukáš Stejskal, Stanislava Mašlejová, Yvona Brychtová, Lucie Bezděková, Tomáš Papajík, Daniel Lysák, Marek Trněný, Lukáš Smolej, Michael Doubek
Publikováno v:
Annals of Hematology. 102:811-817
Autor:
Vítězslav Bryja, Šárka Pospíšilová, Jiří Mayer, Alois Kozubík, Michael Doubek, Yvona Brychtová, Boris Tichý, Petra Ovesná, Jana Kotašková, Pavel Krejčí, Jiřina Procházková, Jan Verner, Archana Mishra, Pavlína Janovská, Šárka Pavlová, Karla Plevová, Markéta Kaucká
PDF file - 695K, S. figure 1mRNA from CD19+ cells of healthy individuals. S. figure 2 Expression of Wnt-5a in the samples shown in Fig. 1 was determined by qRT-PCR. S. figure 3 Viability of primary CLL cells stimulated with the indicated compounds ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7daea81d849dc2f44022b07fb8f4d4cd
https://doi.org/10.1158/0008-5472.22400034.v1
https://doi.org/10.1158/0008-5472.22400034.v1
Autor:
Tomas Kozak, David Belada, Yvona Brychtová, Martin Brejcha, Lukas Stejskal, Martin Spacek, Heidi Mocikova, Jana Zuchnická, Martin Simkovic, Renata Urbanova, Irena Zygulova, Michael Doubek, Eduard Cmunt, Lukas Smolej
Publikováno v:
British Journal of Haematology. 193:769-778
Therapeutic options used to be very limited for treatment-naive elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) before the introduction of chemo-immunotherapy. Because dose-reduced fludarabine-based r
Autor:
Marcela Zenatova, Šárka Pospíšilová, Nikola Tom, Yvona Brychtová, Karla Plevová, Jitka Malčíková, Barbara Dvorackova, Šárka Pavlová, Jakub Hynšt, Jiri Mayer, Michael Doubek, Lenka Radová, Karol Pál, Boris Tichy, Kristyna Zavacka, Anna Panovská, Barbara Kunt Vonkova, Jana Kotašková, Eva Ondroušková
Publikováno v:
Blood
Patients with chronic lymphocytic leukemia (CLL) with TP53 mutations with a >10% variant allele frequency (VAF) are often refractory to chemotherapy and benefit from targeted therapy. Malcikova and colleagues correlated TP53 mutations with
Key P
Key P
Autor:
Hana Skuhrová Francová, Magdalena von Jagwitz-Biegnitz, Anna Panovská, Martin Simkovic, Jana Zuchnická, Stanislava Hrobková, Šárka Pospíšilová, Yvona Brychtová, Michael Doubek, Kamila Stránská, Jiri Mayer, Lenka Radová, Lekaa Mohammadova, Renata Urbanova, Martin Spacek, Hana Škabrahová, Karla Plevová, Lukas Smolej
Publikováno v:
Biomedical Papers, Vol 164, Iss 4, Pp 425-434 (2020)
Aims: This is a nation-wide survey of chronic lymphocytic leukemia (CLL) patients at six large hematology centers in the Czech Republic. The aim was to identify specific populations, social, and health characteristics of CLL subgroups divided accordi
Autor:
Hynek Poul, Šárka Pospíšilová, Eva Koriťáková, Jan Novák, Michael Doubek, Lukas Smolej, Lucie Nekvindová, Lucie Němcová, Martin Spacek, Jana Zuchnická, Daniel Lysák, Karla Plevová, Filip Vrbacký, Renata Urbanova, Tomas Papajik, Yvona Brychtová, Stanislava Mašlejová, David Starostka, Martin Brejcha, Martin Simkovic, Pavel Vodárek, Anna Panovská
Publikováno v:
Hematological Oncology. 38:509-516
Until recently, a combination of anti-CD20 antibody plus less intensive chemotherapy was a standard of care in elderly population with previously untreated chronic lymphocytic leukemia (CLL). The aim of this observational study was to retrospectively
Autor:
Stanislav Drápela, Miroslav Boudny, Josef Jaroš, Michaela Špunarová, Jan Verner, Prashant Khirsariya, Zuzana Jašková, Kamil Paruch, Yvona Brychtová, Marie Kasparkova, Jana Zemanová, Jiri Mayer, Marek Borsky, Václav Šeda, Jana Černá, Martin Trbušek, Alexandra Oltová, Marek Mráz, Karel Souček
Publikováno v:
Haematologica
Introduction of small-molecule inhibitors of B-cell receptor signaling and BCL2 protein significantly improves therapeutic options in chronic lymphocytic leukemia. However, some patients suffer from adverse effects mandating treatment discontinuation
Autor:
Sonali Sharma, Marek Mráz, Veronika Sandova, Yvona Brychtová, Gabriela Mladonická Pavlasová, Matthew S. Davids, Jiri Mayer, Šárka Pospíšilová, Veronika Palusova, Stacey M. Fernandes, Michael Doubek, Anna Panovská, Václav Šeda, Katerina Cerna, Jennifer R. Brown
Publikováno v:
Haematologica
Autor:
Viera Hrabčáková, Marek Borsky, Anna Panovská, Jitka Novotná, Michael Doubek, Petr Muller, Marek Mráz, Jiri Mayer, Martin Trbušek, Yvona Brychtová
Publikováno v:
Leukemia research. 111
The in vivo rituximab effects in B cell malignancies are only partially understood. Here we analyzed in a large chronic lymphocytic leukemia (CLL) cohort (n = 80) the inter-patient variability in CLL cell count reduction within the first 24 h of ritu
Autor:
Milos Kudelka, Jan Molinsky, Gayane Manukyan, Renata Urbanova, Martin Simkovic, Eliska Ochodkova, Peter Turcsanyi, Pavlina Ryznerova, Ondrej Janca, Jan Novák, Eva Kriegova, Zuzana Mikulková, David Starostka, Tomas Papajik, Yvona Brychtová, Lekaa Mohammad, Martin Dihel, Jakub Savara
Publikováno v:
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Background: The tissue microenvironment in chronic lymphocytic leukemia (CLL) plays a key role in promoting neoplastic cell survival, proliferation, and drug resistance. There is a lack of complex characterization of CLL blood microenvironment and it